Recommendations for Use of Everolimus After Heart Transplantation: Results From a Latin-American Consensus Meeting

Transplantation Proceedings

Volumn 38, Issue 3, 2006, Pages 937-942

  Bocchi, E A ^a   Ahualli, L ^b   Amuchastegui, M ^c   Boullon, F ^d   Cerutti, B ^e   Colque, R ^f   Fernandez, D ^g   Fiorelli, A ^c   Olaya, P ^h   Vulcado, N ^f   Perrone, S V ⁱ  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^c HOSPITAL PRIVADO   (Argentina)

^d HOSPITAL FRANCÉS   (Argentina)

^e ICI   (Uruguay)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g Clinica Cardiovascular Santa Maria   (Colombia)

^h FUNDACIÓN VALLE DEL LILI   (Colombia)

ⁱ FLENI   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; ERYTHROMYCIN; EVEROLIMUS; FINGOLIMOD; FLUCONAZOLE; FLUINDOSTATIN; FOLLITROPIN; ITRACONAZOLE; KETOCONAZOLE; LUTEINIZING HORMONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SIMVASTATIN; TACROLIMUS; TESTOSTERONE;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CHAGAS DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERLIPIDEMIA; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; POLYNEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SOUTH AND CENTRAL AMERICA; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VIRUS INFECTION;

CONSENSUS DEVELOPMENT CONFERENCES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LATIN AMERICA; SAFETY; SIROLIMUS;

EID: 33646115826     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.049     Document Type: Article

References (41)

1. Taylor D.O., Edwards L.B., and Boucek M.M. The Registry of the International Society for Heart and Lung Transplantation. twenty-first official adult heart transplantation report-2004. J Heart Lung Transplant 23 (2004) 796
2. Valantine H., and Zuckermann A. From clinical trials to clinical practice. an overview of certican® (everolimus) in heart transplantation. J Heart Transplant 24 (2005) S185
3. Kobashigawa J., Muller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507
4. Eisen H.J., Kobashigawa J., Keogh A., et al. J Heart Lung Transplant 24 (2005) 517
5. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 (2004) 861
6. Bohler T., Waiser J., Budde K., et al. The in vivo effect of rapamicina dervate SDZ RAD on lymphocyte proliferation. Transplant Proc 30 (1998) 2195
7. Schuurnan H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivate. synergism with cyclosporine. Transplantation 64 (1997) 32
8. Nikolova Z., Hof A., Baumlin Y., et al. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl Immunol 8 (2000) 115
9. Reis A., Megahed M., Reinhard T., et al. Coadministration of the new macrolide immunosuppressive RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70 (2000) 1397
10. Delaney M.P., Higgins R.M., and Morris A.G. FK506 and the rapamycin analogue, SDZ RAD do not have antagonistic effects on lymphocytes from renal transplant patients. Am J Transpl 1 Suppl 1 (2001) 301 abstract
11. Viklicky O., Zou H., Muller V., et al. SDZ-RAD prevents manifestations of chronic rejection in rat renal allografts. Transplantation 69 (2000) 497
12. Shuurman H.J., Pally C., Weckbecker G., et al. SDZ RAD inhibits cold ischemic-induced vascular remodeling. Transplant Proc 31 (1999) 1024
13. Salminen U.S., Alho H., Tasknen E., et al. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model. Transplant Proc 30 (1998) 2204
14. Weckbecker G., Caballero V., Court M., et al. Differential effects of FTY720, RAD, and CsA on signs of chronic rejection in the rat tracheal allograft model. Graft 5 (2002) 145
15. Matsumoto Y., Hof A., Baumlin Y., et al. Differential effect of cyclosporin A and SDZ RAD on neointima formation of carotid allograft in apolipoprotein E-deficient mice. Transplantation 76 (2003) 1166
16. Salminen U.S., Maasita P.K., Taskien, et al. Prevention of small airway obliteration in a suine heterotopic lung allograft model. J Heart Lung Transplant 19 (2000) 193
17. Pirron U., Kovarik J.M., Eisen H., et al. Longitudinal pharmacokinetics of a everolimus in de novo heart transplantation patients and its influence on cyclosporine. Transplantation 74 suppl (2002) 211
18. Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of food on everolimus absortion. quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 22 (2002) 154
19. Jacobsen W., Serkova N., Hausen B., et al. Comparison of in vivo metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 33 (2001) 514
20. Kovarik J.M., Sabia H.D., Figueiredo J., et al. Influence of hepatic impairment on everolimus pharmacokinetics. implications for dose adjustment. Clin Pharmacol Ther 70 (2001) 423
21. Kovarik J.M., Kaplan B., Silva H.T., et al. Pharmacokinetics of an everolimus-cyplosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 3 (2003) 606
22. Eisen H.J., Tuzcu M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847
23. Kobashigawa J., Hare J., Eisen H., et al. Everolimus in cardiac transplantation 48 months results. Am J Transpl (2005) abstr 374
24. © (Everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Transplant 24 (2005) S206
25. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican ®) 12-months safety and efficacy versus mycophenolate mofetil in the novo renal transplant recipients. Transplantation 78 (2004) 1532
26. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican) 12 months safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 24 (2005) S206
27. Starling R.C., Hare J.M., Hauptan P., et al. Therapeutic drug monitoring for everolimus in heart transplantation recipients based on exposure-effect modeling. Am J Transplantation 4 (2004) 2126
28. Kramer B.K., Neumayer H.H., Stahl R., et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc 37 (2005) 1601
29. Bacal F., Silva C.P., Bocchi E.A., et al. Mychophenolate mofetil increased Chagas' disease reactivation in heart transplanted patients. comparison between two different protocols. Am J Transplant 5 (2005) 2017
30. Bocchi E.A., Bellotti G., Mocelin A.O., et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 61 (1996) 1727
31. Bocchi E.A., Bellotti G., Uip D., et al. Long-term follow-up after heart transplantation in Chagas' disease. Transplant Proc 25 (1993) 1329
32. Bocchi E.A., Fiorelli A., and Guidelines Group. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg 71 (2001) 1833
33. Bocchi E.A., Fiorelli A., and First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology. The Brazilian experience with heart transplantation. a multicenter report. J Heart Lung Transplant 20 (2001) 637
34. Urinovsky F., Salomone O., Amuchâstegui M., et al. Morbimortalidad de los pacientes con miocardiopatia chagásica y transplante cardi{dotless}́aco. Experiencia inicial. Rev Arg Cardiol 71 (2003) 325
35. Kovarik J.M., Hartmann S., Huber M., et al. Pharmacokinetic and pharmacodynamic assessment of HMG-CoA reductase inhibitors when coadministered with Everolimus. J Clin Pharmacology 42 (2002) 222
36. Lehmkuhl H., and Hetzer R. Clinical experience with Certican® (Everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 24 (2005) S201
37. Bocchi E.A., Higuchi M.L., Vieira M.L., et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 17 (1998) 399
38. Boyd J., Arabshahi L., Roberts M., et al. A new FPIA immunoassay for the quantitative determination of everolimus in whole blood. Thera Drug Monit 27 (2005) 213
39. Cantarovich M., Elstein E., de Varennes B., et al. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplantation. Transplantation 68 (1999) 1839
40. Delgado D.H., Rao V., Cusimano R.J., et al. Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation. J Heart Lung Transplant 21 (2002) 102
41. Eisen H., and Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Transplant 23 suppl (2004) S207